TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04634877

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: ≥4500 cGY given according to local practice, at the discretion of the investigator

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiotherapy (EBRT)
Description: ≥4500 cGY given according to local practice, at the discretion of the investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (as radiosensitizer)
Description: If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (as radiosensitizer)
Description: If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Given according to local practice, at the discretion of the investigator

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Brachytherapy
Description: Given according to local practice, at the discretion of the investigator
Study: NCT05862233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIL62
Description: An intravenous (IV) infusion of 1000 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d in 2 divided doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks±3 days until the target blood concentration of 125\~175 ng/ mL was reached.If the treatment is effective,cyclosporine would be reduced by about 1/2 of the original dose each month, and discontinued after 2 months.
Study: NCT05064280

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Given by IV (200 mg IV D1 Q3W)

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Given by IV (200 mg IV D1 Q3W)

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Given by IV (200 mg IV D1 Q3W)

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Given by PO (20 mg PO QD)

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Given by PO (20 mg PO QD)

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Given by PO (20 mg PO QD)
Study: NCT04936490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crocin
Description: 15 mg/d
Study: NCT04885530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
Study: NCT04936490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg/d
Study: NCT06148259

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: International prostate symptom score
Description: Questionnaire of 8 questions to be administered to all patients about prostate symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: International prostate symptom score
Description: Questionnaire of 8 questions to be administered to all patients about prostate symptoms

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of prostate volume
Description: Measurements using ultrasound

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Assessment of prostate volume
Description: Measurements using ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh sleep quality Index
Description: Questionnaire to assess quality of sleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pittsburgh sleep quality Index
Description: Questionnaire to assess quality of sleep

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Glycated hemoglobin
Description: Measures control of diabetes

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Glycated hemoglobin
Description: Measures control of diabetes
Study: NCT06447974

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposure mitigations
Description: Behavioural interventions with an aim to reduce exposure by targeting occurrences of high exposure
Study: NCT05034575

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eye Tracking Technology Sensor
Description: Eye tracking will be performed using Tobii Pro eye tracking technology sensor (Tobii Pro Fusion, Stockholm, Sweden), providing binocular eye tracking up to 250 Hz. The sensor, positioned on the inferior aspect of the computer monitor, reflects infrared (IR) light beams off of each cornea and are subsequently captured.
Study: NCT06270511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-337395
Description: Administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-337395
Description: Administered as an oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an oral suspension.
Study: NCT04885530

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT06552689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sutra Hemi-valve Transcatheter Mitral Valve Replacement (TMVR) System
Description: Trans-septal Sutra Hemi-valve TMVR System to treat mitral regurgitation
Study: NCT05859880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention
Description: 4 videoconference-delivered group-based expressive writing sessions
Study: NCT05267015

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingival coverage using coronally advanced flap and a connective tissue graft
Description: A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using a subepithelial connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingival coverage using coronally advanced flap and platelet rich fibrin membranes
Description: A coronally advanced flap is applied for recession coverage in the maxilla in a split-mouth randomized trial using platelet rich fibrin membranes
Study: NCT04885530

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.
Study: NCT05004779

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human stem cell conditioned media was applied after non-ablative laser therapy
Description: After laser treatment on hypertrophic scars, human stem cell media was applied to one side

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: normal saline was applied after non ablative laser therapy
Description: physiological saline was applied to the other side.
Study: NCT06417905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercises
Description: strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video based exercises
Description: strengthening deep neck flexors, serratus anterior middle and lower trapez stretchening upper trapezius, levator scapula
Study: NCT06045169

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Post Isometric Relaxation
Description: Post isometric relaxation with participants using 20% of their maximum voluntary contraction will be given to global muscles of core commonly involved in primary dysmenorrhea glutus maximus, Illiopsoas and pirifirmis. Post isometric contraction will be held for 6 to 10 seconds followed by 15 o 30 seconds stretch, rst time will be 5 seconds in between repetations and number of repetations will be 3-5.
Study: NCT04885530

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast sodium is a white to off-white powder. The 10 mg montelukast tablets are beige, rounded square-shaped, biconvex, film-coated tablets. Each tablet contains 10.4 mg of montelukast sodium, which is equivalent to 10 mg montelukast. All packaging will be labeled to indicate that the product is for investigational use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin IR tablets contain the active metformin hydrochloride and inactive ingredients including povidone and magnesium stearate. Commercially available metformin 500 mg tablets will be provided.
Study: NCT05278715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Dose of carboplatin is adjusted for age (over 1 year old, full dose, 220 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Dose of vincristine is adjusted for age (over 1 year old, full dose, 1.5 mg/m\^2; 6 months of age or less, 66 percent of the full dose; 7 to 12 months of age, 80 percent). Maximum dose is 2 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin (rh-ES) is administrated at a dose of 15mg daily, for 14 consecutive days every 3 weeks.
Study: NCT06552416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401-OTS
Description: MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401-OTS
Description: MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401-OTS
Description: MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401-OTS
Description: MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-401-OTS
Description: MT-401-OTS is an off the shelf cellular therapy product given by IV infusion through either a peripheral or central line.
Study: NCT04600622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rural Diabetes One-Day Education and Care program (R-D1D)
Description: One time, 5.5-hour multi-disciplinary diabetes self-management education and support intervention delivered via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Materials
Description: Diabetes Education Materials
Study: NCT05859880

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expressive writing intervention
Description: 4 videoconference-delivered group-based expressive writing sessions
Study: NCT04304495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Prevention
Description: The intervention arm participants will receive a physical therapy and pharmacy consults as well as Apple Watch training and an Apple Watch device to test memory and mobility during the ED visit and during our home visits.
Study: NCT05443061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Subcutaneous nitroglycerin injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Subcutaneous normal saline injection to decrease the incidence of radial arterial occlusion after arterial catheter removal in pediatric patients.
Study: NCT05557435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk odor
Description: The intervention of the experimental group was to stimulate the odor of breast milk. The researchers informed the mothers of premature infants in advance on the day before the experiment, and collected the breast milk samples in the morning before eating on the day of the experiment (excluding the influence of the odor of breast milk by diet). The researchers took a clean cotton ball so that the breast milk was completely absorbed by the cotton ball, and placed the cotton ball that absorbed breast milk at a distance of 5cm next to the mouth and nose of the premature infant, so that the premature infant could receive the smell of breast milk.~The intervention of the control group was to stimulate the smell of distilled water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04776005

Intervention type: OTHER
Intervention: Data collection
Description: Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.

Intervention type: OTHER
Intervention: Data collection
Description: Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.

Intervention type: OTHER
Intervention: Data collection
Description: Assessment of the efficacy and immunogenicity of the anti-Sars-COv2 vaccines in patients treated for malignant pathology.
Study: NCT06145607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-CLS-7262
Description: ABBV-CLS-7262
Study: NCT05957055

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental training in behavior management
Description: Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: parental training in behavior management
Description: Parental training in behavior management - online group sessions (4-6 families within group) with trained specialist, 10 once-weekly sessions. To continue to pharmacotherapy, the parents/legal guardians are required to participate in at least 8 out of 10 sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: Once-daily pharmacotherapy with lisdexamfetamine (608137-32-2, SUB32146), administered orally, for a duration of 6 months with initial dose of 30mg and dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 20mg steps).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Once-daily pharmacotherapy with methylphenidate (prolonged-release tablet, 298-59-9, SUB03254MIG), administered orally, for a duration of 6 months with initial of 18mg dose optimization for 5-7 weeks (visits after 1st, 3rd and 5th week of therapy to adjust dose, in 18mg steps).
Study: NCT04409080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7257
Description: Administered by intravenous (IV) infusion, in Part A and B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7257
Description: Administered by intravenous (IV) infusion, in Part A and B.
Study: NCT05534113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib Envafolimab
Description: Subjects will receive Almonertinib treatment for 6-8 weeks after enrollment, and receive ctDNA detection and radiography assessment again.~If the EGFR mutation is positive, according to the patient's condition and clinical actual situation, subjects will receive combination therapy scheme, follow-up once every 6 weeks. The treatment will continue until the disease progress assessed by radiography.~If the EGFR mutation turns negative and stable radiographically deep response, stop Almonertinib treatment and receive the relevant assessment before immunotherapy and receive Envafolimab treatment，and follow-up once every 6 weeks. The treatment of Envafolimab will continue until the EGFR mutation is positive again or disease progress assessed by radiography.
Study: NCT05300152

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry Protocol for Osteopontin Antibody
Description: will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immunohistochemistry Protocol for Osteopontin Antibody
Description: will be carried out via avidin-biotin-peroxidase complex method using a VECTASTAIN ABC Kit . Sections will be deparaffinized by xylene and graded ethanol then treated with 20 µg/ml Proteinase K for 10 min. to prevent endogenous peroxidase activity, sections is incubated for 30 min in 0.3% H2O2/methanol then treated with 0.1% blocking serum albumin and incubated with primary antibody for 30 min. Rabbit polyclonal anti-osteopontin and goat polyclonal anti-RANKL will be used. dilution of primary antibodies used will be osteopontin (1 : 6000-8000). After being washed with phosphate-buffered saline several times, sections will be incubated with biotinylated IgG for 30 min and subsequently with streptavidin-horseradish peroxidase for 30 min. Following several washes with phosphate-buffered saline, 3,3'-diaminobenzidine substrate will be applied. As a negative control, non-immune serum will be used instead of primary antibody.